日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Cardiovascular disease and compliance with lipid-lowering therapy among young individuals with familial hypercholesterolemia in Norway - A register study

挪威年轻家族性高胆固醇血症患者的心血管疾病及降脂治疗依从性——一项登记研究

期刊:American Journal of Preventive Cardiology
影响因子:5.9
doi:10.1016/j.ajpc.2025.101043
Langslet, Gisle; Asprusten, Emil A; Igland, Jannicke; Holven, Kirsten B; Bogsrud, Martin P; Retterstøl, Kjetil
心血管疾病
心血管
代谢
发表日期：2025
文献求助 收藏

Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

在北欧2型糖尿病患者中，与DPP-4抑制剂相比，恩格列净的使用与全因死亡率、心力衰竭住院率和终末期肾病风险降低相关：来自EMPRISE（恩格列净比较疗效和安全性）研究的结果

期刊:Journal of Diabetes Research
影响因子:3.4
doi:10.1155/2024/6142211
Langslet, Gisle; Nyström, Thomas; Vistisen, Dorte; Carstensen, Bendix; Grip, Emilie Toresson; Casajust, Paula; Tskhvarashvili, Giorgi; Hoti, Fabian; Klement, Riho; Karlsdotter, Kristina; Tuovinen, Mikko; Ofstad, Anne Pernille; Lajer, Maria; Shay, Christina; Koeneman, Lisette; Farsani, Soulmaz Fazeli; Niskanen, Leo; Halvorsen, Sigrun
糖尿病
心力衰竭
心血管
代谢
发表日期：2024
文献求助 收藏

Lipoprotein(a) in children and adolescents with genetically confirmed familial hypercholesterolemia followed up at a specialized lipid clinic

在专门的脂质诊所接受随访的、经基因检测确诊为家族性高胆固醇血症的儿童和青少年的脂蛋白(a)水平

期刊:Atherosclerosis Plus
影响因子:2.1
doi:10.1016/j.athplu.2024.06.002
Johansen, Anja K; Bogsrud, Martin P; Thoresen, Magne; Christensen, Jacob J; Narverud, Ingunn; Langslet, Gisle; Svilaas, Tone; Retterstøl, Kjetil; Holven, Kirsten B
代谢
发表日期：2024
文献求助 收藏

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia

与二肽基肽酶-4抑制剂相比，恩格列净与成人（无论是否患有心血管疾病）心血管风险降低相关：来自欧洲和亚洲的恩格列净疗效和安全性比较研究（EMPRISE）结果

期刊:Cardiovascular Diabetology
影响因子:10.6
doi:10.1186/s12933-023-01963-9
Vistisen, Dorte; Carstensen, Bendix; Elisabetta, Patorno; Lanzinger, Stefanie; Tan, Elise Chia-Hui; Yabe, Daisuke; Kim, Dae Jung; Sheu, Wayne H-H; Melzer-Cohen, Cheli; Holl, Reinhard W; Núñez, Júlio; Ha, Kyoung Hwa; Halvorsen, Sigrun; Langslet, Gisle; Karasik, Avraham; Nyström, Thomas; Niskanen, Leo; Guleria, Sonia; Klement, Riho; Carrasco, Marc; Foersch, Johannes; Shay, Christina; Koeneman, Lisette; Hoti, Fabian; Farsani, Soulmaz Fazeli; Khunti, Kamlesh; Zaccardi, Francesco; Subramanian, Anuradhaa; Nirantharakumar, Krishnarajah
心血管疾病
心血管
发表日期：2023
文献求助 收藏

Young women with familial hypercholesterolemia have higher LDL-cholesterol burden than men: Novel data using repeated measurements during 12-years follow-up

患有家族性高胆固醇血症的年轻女性的低密度脂蛋白胆固醇水平高于男性：基于12年随访期间重复测量的新数据

期刊:Atherosclerosis Plus
影响因子:2.1
doi:10.1016/j.athplu.2023.01.001
Johansen, Anja K; Bogsrud, Martin P; Christensen, Jacob J; Rundblad, Amanda; Narverud, Ingunn; Ulven, Stine; Langslet, Gisle; Retterstøl, Kjetil; Holven, Kirsten B
代谢
发表日期：2023
文献求助 收藏

Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME(®)

EMPA-REG OUTCOME(®) 研究中的心血管结局和 LDL 胆固醇水平

期刊:
影响因子:
doi:10.1177/1479164120975256
Langslet, Gisle; Zinman, Bernard; Wanner, Christoph; Hantel, Stefan; Espadero, Rosa-Maria; Fitchett, David; Johansen, Odd Erik
代谢
发表日期：2020
文献求助 收藏

Efficacy and Safety of Alirocumab 300 mg Every 4 Weeks in Individuals With Type 2 Diabetes on Maximally Tolerated Statin

在接受最大耐受剂量他汀类药物治疗的 2 型糖尿病患者中，每 4 周一次 300 mg 阿利西尤单抗的疗效和安全性

期刊:Journal of Clinical Endocrinology & Metabolism
影响因子:5.1
doi:10.1210/jc.2018-02703
Müller-Wieland, Dirk; Rader, Daniel J; Moriarty, Patrick M; Bergeron, Jean; Langslet, Gisle; Ray, Kausik K; Manvelian, Garen; Thompson, Desmond; Bujas-Bobanovic, Maja; Roth, Eli M
糖尿病
代谢
发表日期：2019
文献求助 收藏

The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions

2型糖尿病心力衰竭负担——病理生理学和干预措施综述

期刊:Heart Failure Reviews
影响因子:4.2
doi:10.1007/s10741-018-9685-0
Ofstad, Anne Pernille; Atar, Dan; Gullestad, Lars; Langslet, Gisle; Johansen, Odd Erik
糖尿病
心力衰竭
心血管
代谢
发表日期：2018
文献求助 收藏

Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study

依洛尤单抗治疗高胆固醇血症的长期降低低密度脂蛋白胆固醇疗效、持久性和安全性：开放标签 OSLER-1 扩展研究长达 4 年的结果

期刊:Jama Cardiology
影响因子:14.1
doi:10.1001/jamacardio.2017.0747
Koren, Michael J; Sabatine, Marc S; Giugliano, Robert P; Langslet, Gisle; Wiviott, Stephen D; Kassahun, Helina; Ruzza, Andrea; Ma, Yuhui; Somaratne, Ransi; Raal, Frederick J
红斑狼疮
代谢
发表日期：2017
文献求助 收藏

Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin

在服用二甲双胍的 2 型糖尿病患者中，卡格列净与格列美脲相比，可同时降低糖化血红蛋白 (HbA1c) 和体重。

期刊:Diabetes Therapy
影响因子:2.6
doi:10.1007/s13300-016-0163-1
Leiter, Lawrence A; Langslet, Gisle; Vijapurkar, Ujjwala; Davies, Michael J; Canovatchel, William
糖尿病
代谢
发表日期：2016
文献求助 收藏